AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 9th, 2014 • Ambrx Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) to Executive Employment Agreement is made effective as of June 6, 2014. This Amendment amends the Executive Employment Agreement, dated as of January 6, 2013, by and between Ambrx, Inc., a Delaware corporation (the “Company”), and Lawson Macartney (“Executive”) (the “Agreement”).
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 9th, 2014 • Ambrx Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) to Executive Employment Agreement is made as of June 6, 2014. This Amendment amends the Executive Employment Agreement, dated as of March 14, 2011, by and between Ambrx, Inc., a Delaware corporation (the “Company”), and Simon Allen (“Executive”) (the “Agreement”). This Amendment will be effective upon the closing of the initial public offering of the Company.
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 9th, 2014 • Ambrx Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) to Executive Employment Agreement is made as of June 6, 2014. This Amendment amends the Executive Employment Agreement, dated as of July 30, 2013, by and between Ambrx, Inc., a Delaware corporation (the “Company”), and Peter Alec Kiener (“Executive”) (the “Agreement”). This Amendment will be effective upon the closing of the initial public offering of the Company.
THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 9th, 2014 • Ambrx Inc • Pharmaceutical preparations
This Third Amendment (this “Amendment”) to Executive Employment Agreement is made as of June 6, 2014. This Amendment amends the Executive Employment Agreement, dated as of February 1, 2004, as amended by the Amendment to Executive Employment Agreement dated as of December 22, 2008 and the Second Amendment to Executive Employment Agreement dated as of February 1, 2014, by and between Ambrx, Inc., a Delaware corporation (the “Company”) and John W. Wallen, III (“Executive”) (the “Agreement”). This Amendment will be effective upon the closing of the initial public offering of the Company.
SECOND AMENDMENT TO SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • June 9th, 2014 • Ambrx Inc • Pharmaceutical preparations
This Second Amendment (this “Amendment”) to Severance and Change in Control Agreement is made as of June 6, 2014. This Amendment amends the Severance and Change in Control Agreement, dated as of July 3, 2007, as amended as of December 22, 2008, by and between Ambrx, Inc., a Delaware corporation (the “Company”) and Cris Calsada (“Executive”) (the “Agreement”). This Amendment will be effective upon the closing of the initial public offering of the Company.
